Unblinding should only be performed by an NHS doctor and should only be considered where knowledge of treatment allocation is essential to guide clinical management. 

For specific anticipated scenarios with advice to unblind, read this guidance on unblinding clinical scenarios.

EJS ACT-PD is a double-blind trial. This means that neither the participant nor their doctors or study team know which treatments they have received.

Participants in EJS ACT-PD trial could be taking:

• Telmisartan – up to 40mg a day

• Terazosin – up to 5mg a day

• Placebo

Unblinding of allocation to trial treatment can be performed if required only in a medical emergency, where knowledge of the participant’s treatment allocation would change immediate clinical management. This can be requested by any treating doctor and performed in medical emergencies.

The doctor requiring the unblinding may contact or notify the participant’s site prior to unblinding to discuss the circumstances if this will not result in a delay to treatment; site contact details (including out-of-hours contact) can be found on the participant’s card.

If it has not been possible to contact the participant’s local site, the trial emergency numbers (also found on the participant's card and on this webpage) can be used to contact the delegated members of the EJS ACT-PD Trial.

However, if it is not possible to contact a member of the trial team via the trial emergency number, the procedure for rapid break of blinding is in place so that unblinding can be performed to not delay treatment.